{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:43Z","timestamp":1759017883341,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clinthera.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:34:25Z","timestamp":1654302865000},"page":"982-997.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib\u00a0+\u00a0Oral Methotrexate Combination"],"prefix":"10.1016","volume":"44","author":[{"given":"Stanley B.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7219-9192","authenticated-orcid":false,"given":"Timothy W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Woolcott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3516-5289","authenticated-orcid":false,"given":"David","family":"Gruben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher W.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.05.002_bib0001","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0003","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/art.41589","article-title":"Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subjects with Rheumatoid Arthritis","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0004","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0006","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0007","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0008","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0009","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0010","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0011","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0012","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0013","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0014","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0016","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amjms.2016.01.010","article-title":"Medication adherence: truth and consequences","volume":"351","author":"Brown","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0017","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13643-019-1014-8","article-title":"Medication adherence influencing factors-an (updated) overview of systematic reviews","volume":"8","author":"Gast","year":"2019","journal-title":"Syst Rev"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/rheumatology\/keaa214","article-title":"Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate","volume":"60","author":"Barton","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0019","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00044011-200626020-00001","article-title":"Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis","volume":"26","author":"Tilling","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12891-016-1254-x","article-title":"Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis","volume":"17","author":"Curtis","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0021","first-page":"213","article-title":"The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate","volume":"59","author":"Hope","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0022","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/PPA.S134924","article-title":"Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients","volume":"11","author":"M\u00fcller","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0023","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40744-020-00200-z","article-title":"Methotrexate discontinuation and dose decreases after therapy with tocilizumab: results from the Corrona rheumatoid arthritis registry","volume":"7","author":"Pappas","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0024","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3899\/jrheum.151212","article-title":"Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review","volume":"43","author":"Curtis","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/acr.22510","article-title":"Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients","volume":"67","author":"Zhang","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0026","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40744-018-0093-7","article-title":"Effect of discontinuation or initiation of methotrexate or glucocorticoids on tofacitinib efficacy in patients with rheumatoid arthritis: a post hoc analysis","volume":"5","author":"Fleischmann","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0027","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1016\/S2665-9913(19)30005-0","article-title":"Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b\/4, non-inferiority trial","volume":"1","author":"Cohen","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0028","unstructured":"PQA Adherence Measures [Pharmacy Quality Alliance website]. 2021. Available at: https:\/\/www.pqaalliance.org\/adherence-measures. Last accessed May 2022."},{"key":"10.1016\/j.clinthera.2022.05.002_bib0029","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3471","article-title":"Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis","volume":"13","author":"Curtis","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0030","first-page":"657","article-title":"Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis","volume":"20","author":"Oladapo","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0031","first-page":"1457","article-title":"Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database","volume":"22","author":"Harnett","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0032","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.clinthera.2016.03.038","article-title":"Initial experience with tofacitinib in clinical practice: treatment patterns and costs of tofacitinib administered as monotherapy or in combination with conventional synthetic DMARDs in 2 US health care claims databases","volume":"38","author":"Harnett","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0033","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.40493","article-title":"Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized controlled trial (COMP-ACT)","volume":"70","author":"Kremer","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2022.05.002_bib0034","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/annrheumdis-2013-203684","article-title":"The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis","volume":"73","author":"Pope","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:21Z","timestamp":1758963441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0149291822001539"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.05.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib\u00a0+\u00a0Oral Methotrexate Combination","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Pfizer and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}